GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (XTAE:RDHL) » Definitions » Gross Profit

Redhill Biopharma (XTAE:RDHL) Gross Profit : ₪57.0 Mil (TTM As of Jun. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Redhill Biopharma Gross Profit?

Redhill Biopharma's gross profit for the three months ended in Jun. 2023 was ₪3.7 Mil. Redhill Biopharma's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was ₪57.0 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Redhill Biopharma's gross profit for the three months ended in Jun. 2023 was ₪3.7 Mil. Redhill Biopharma's Revenue for the three months ended in Jun. 2023 was ₪6.7 Mil. Therefore, Redhill Biopharma's Gross Margin % for the quarter that ended in Jun. 2023 was 55.12%.

Redhill Biopharma had a gross margin of 55.12% for the quarter that ended in Jun. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Redhill Biopharma was 85.03%. The lowest was 42.39%. And the median was 46.99%.

Warning Sign:

Redhill Biopharma Ltd gross margin has been in long-term decline. The average rate of decline per year is -7.4%.


Redhill Biopharma Gross Profit Historical Data

The historical data trend for Redhill Biopharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Gross Profit Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.03 102.39 135.51 106.10 11.45

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.20 15.66 7.41 3.69 -

Competitive Comparison of Redhill Biopharma's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Gross Profit falls into.



Redhill Biopharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Redhill Biopharma's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=24.342 - 12.894
=11.4

Redhill Biopharma's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=6.695 - 3.005
=3.7

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪57.0 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Redhill Biopharma's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=3.7 / 6.695
=55.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Redhill Biopharma  (XTAE:RDHL) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Redhill Biopharma had a gross margin of 55.12% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Redhill Biopharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (XTAE:RDHL) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.